PHAS PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowen’s 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm – 1:50 pm ET.

Interested parties can access the live and archived webcasts of the virtual session on the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com. The webcast replay will be available for 90 days after the conclusion of the live presentation.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. PhaseBio’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly VIP receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com, and follow us on Twitter @PhaseBio and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220224006067/en/

PhaseBio Investor Contact: John Sharp Chief Financial Officer (610) 981-6506 john.sharp@phasebio.com

PhaseBio Media Contact: Will Zasadny Canale Communications, Inc. (619) 961-8848 will.zasadny@canalecomm.com

Grafico Azioni PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Storico
Da Giu 2023 a Giu 2024